{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:27Z","timestamp":1793367147920,"version":"4.5.0"},"reference-count":116,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen implicated in tumor invasion, which is highly expressed in mesothelioma and lung, pancreas, breast, ovarian, and other cancers. Its low-level expression in mesothelia, however, commands thoughtful therapeutic interventions. Encouragingly, recent clinical trials evaluating active immunization or immunoconjugates in patients with pancreatic adenocarcinoma or mesothelioma have shown responses without toxicity. Altogether, these findings and preclinical CAR therapy models using either systemic or regional T-cell delivery argue favorably for mesothelin CAR therapy in multiple solid tumors.<\/jats:p>\n                  <jats:p>Significance: Recent success obtained with adoptive transfer of CAR T cells targeting CD19 in patients with refractory hematologic malignancies has generated much enthusiasm for T-cell engineering and raises the prospect of implementing similar strategies for solid tumors. Mesothelin is expressed in a wide range and a high percentage of solid tumors, which we review here in detail. Mesothelin CAR therapy has the potential to treat multiple solid malignancies. Cancer Discov; 6(2); 133\u201346. \u00a92015 AACR.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-15-0583","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T21:53:31Z","timestamp":1445896411000},"page":"133-146","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":434,"title":["Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors"],"prefix":"10.1158","volume":"6","author":[{"given":"Aurore","family":"Morello","sequence":"first","affiliation":[{"name":"1Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"1Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[{"name":"1Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"2Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"2022060700173625800_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1535-6108(03)00113-2","article-title":"Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction","volume":"3","author":"Ho","year":"2003","journal-title":"Cancer Cell"},{"key":"2022060700173625800_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022060700173625800_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2022060700173625800_bib4","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060700173625800_bib6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060700173625800_bib7","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.","volume":"10","author":"Kochenderfer","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060700173625800_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"key":"2022060700173625800_bib10","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm.","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"2022060700173625800_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T Cells.","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"2022060700173625800_bib12","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib13","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2022060700173625800_bib15","doi-asserted-by":"crossref","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib16","first-page":"466","article-title":"Mesothelin-targeted immunotherapies for malignant pleural mesothelioma","volume":"1","author":"Villena-Vargas","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"2022060700173625800_bib17","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib18","first-page":"181","article-title":"Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium","volume":"52","author":"Chang","year":"1992","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1349-7006.2007.00715.x","article-title":"Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells","volume":"99","author":"Sapede","year":"2008","journal-title":"Cancer Sci"},{"key":"2022060700173625800_bib20","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2022060700173625800_bib21","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060700173625800_bib24","doi-asserted-by":"crossref","first-page":"e114900","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"key":"2022060700173625800_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt\/PI3K\/NF-kappaB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol Cancer"},{"key":"2022060700173625800_bib26","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci Rep"},{"key":"2022060700173625800_bib27","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"2022060700173625800_bib28","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein\u2013a blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer"},{"key":"2022060700173625800_bib29","doi-asserted-by":"crossref","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Thomas","year":"2015","journal-title":"Oncotarget"},{"key":"2022060700173625800_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","article-title":"Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer","volume":"107","author":"Einama","year":"2012","journal-title":"Br J Cancer"},{"key":"2022060700173625800_bib31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00535-013-0773-6","article-title":"C-ERC\/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma","volume":"49","author":"Kawamata","year":"2014","journal-title":"J Gastroenterol"},{"key":"2022060700173625800_bib32","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"2022060700173625800_bib33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022060700173625800_bib34","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4461","article-title":"Functional genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types","author":"Lamberts","year":"2015  1","journal-title":"Oncotarget"},{"key":"2022060700173625800_bib35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib36","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060700173625800_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022060700173625800_bib38","doi-asserted-by":"crossref","first-page":"e88133","DOI":"10.1371\/journal.pone.0088133","article-title":"Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"2022060700173625800_bib39","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-04-2304","article-title":"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients","volume":"11","author":"Ho","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib40","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib41","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib42","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"2022060700173625800_bib43","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int J Cancer"},{"key":"2022060700173625800_bib44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","article-title":"A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity","volume":"8","author":"Feng","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2022060700173625800_bib45","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2022060700173625800_bib47","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060700173625800_bib48","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib49","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib50","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"2022060700173625800_bib51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib52","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2022060700173625800_bib54","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib55","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","article-title":"Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases","volume":"73","author":"Riese","year":"2013","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib56","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/ijc.25960","article-title":"Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling","volume":"129","author":"Hombach","year":"2011","journal-title":"Int J Cancer"},{"key":"2022060700173625800_bib57","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","article-title":"Generation of potent T cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors","volume":"3","author":"Wang","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022060700173625800_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PPO.0000000000000029","article-title":"NKG2D CARs as cell therapy for cancer","volume":"20","author":"Sentman","year":"2014","journal-title":"Cancer J"},{"key":"2022060700173625800_bib60","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"key":"2022060700173625800_bib61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.gt.3301051","article-title":"Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production","volume":"7","author":"Weijtens","year":"2000","journal-title":"Gene Ther"},{"key":"2022060700173625800_bib62","article-title":"A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity","author":"Song","year":"2015  19","journal-title":"Oncotarget"},{"key":"2022060700173625800_bib63","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","article-title":"T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity","volume":"173","author":"Chmielewski","year":"2004","journal-title":"J Immunol"},{"key":"2022060700173625800_bib64","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2022060700173625800_bib66","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/mt.2011.9","article-title":"CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation","volume":"19","author":"Kofler","year":"2011","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib67","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib68","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"2022060700173625800_bib69","first-page":"3928","article-title":"Bypassing immunization: optimized design of \u201cdesigner T cells\u201d against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA","volume":"5","author":"Nolan","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200005000-00006","article-title":"Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor","volume":"23","author":"Beecham","year":"2000","journal-title":"J Immunother"},{"key":"2022060700173625800_bib71","doi-asserted-by":"crossref","first-page":"450291","DOI":"10.1155\/2013\/450291","article-title":"Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse","volume":"2013","author":"Gonzalez","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2022060700173625800_bib72","first-page":"Unit14 21","article-title":"Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden","author":"Servais","year":"2011","journal-title":"Curr Protoc Pharmacol"},{"key":"2022060700173625800_bib73","doi-asserted-by":"crossref","first-page":"e26722","DOI":"10.1371\/journal.pone.0026722","article-title":"An in vivo platform for tumor biomarker assessment","volume":"6","author":"Servais","year":"2011","journal-title":"PLoS One"},{"key":"2022060700173625800_bib74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022060700173625800_bib75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2022060700173625800_bib76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14653240600620176","article-title":"Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma","volume":"8","author":"Cooper","year":"2006","journal-title":"Cytotherapy"},{"key":"2022060700173625800_bib77","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060700173625800_bib78","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"2022060700173625800_bib79","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1002\/cncr.28883","article-title":"Translational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma","volume":"120","author":"Adusumilli","year":"2014","journal-title":"Cancer"},{"key":"2022060700173625800_bib80","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"2022060700173625800_bib81","doi-asserted-by":"crossref","first-page":"e56820","DOI":"10.1371\/journal.pone.0056820","article-title":"Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor","volume":"8","author":"Asai","year":"2013","journal-title":"PLoS One"},{"key":"2022060700173625800_bib82","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/mt.2010.185","article-title":"T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib83","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"2022060700173625800_bib84","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-beta signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene Therapy"},{"key":"2022060700173625800_bib85","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","article-title":"Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity","volume":"191","author":"Ankri","year":"2013","journal-title":"J Immunol"},{"key":"2022060700173625800_bib86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","article-title":"Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor","volume":"51","author":"Prosser","year":"2012","journal-title":"Mol Immunol"},{"key":"2022060700173625800_bib87","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.jamcollsurg.2014.07.320","article-title":"Mesothelin-targeted T cells gene-engineered with 4-1BB costimulation overcome tumor-mediated immunoinhibition and eradicate established solid tumors","volume":"219","author":"Cherkassky","year":"2014","journal-title":"J Am Coll Surg"},{"key":"2022060700173625800_bib88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2022060700173625800_bib89","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib90","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","article-title":"Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors","volume":"33","author":"Fujisaka","year":"2015","journal-title":"Invest New Drugs"},{"key":"2022060700173625800_bib91","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib92","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"2022060700173625800_bib93","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"2022060700173625800_bib94","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"2022060700173625800_bib95","doi-asserted-by":"crossref","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"2022060700173625800_bib96","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib97","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib98","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"2022060700173625800_bib99","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1182\/blood-2009-09-241398","article-title":"IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice","volume":"115","author":"Markley","year":"2010","journal-title":"Blood"},{"key":"2022060700173625800_bib100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","article-title":"Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition","volume":"20","author":"Perna","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib101","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","article-title":"Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies","volume":"71","author":"Singh","year":"2011","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib102","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell-encoded CD80 and 4\u20131BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"key":"2022060700173625800_bib103","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib104","doi-asserted-by":"crossref","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","article-title":"Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4","volume":"285","author":"Wilkie","year":"2010","journal-title":"J Biol Chem"},{"key":"2022060700173625800_bib105","doi-asserted-by":"crossref","first-page":"e0130518","DOI":"10.1371\/journal.pone.0130518","article-title":"Tumor-targeted human t cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition","volume":"10","author":"Condomines","year":"2015","journal-title":"PLoS One"},{"key":"2022060700173625800_bib106","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022060700173625800_bib107","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/1078-0432.CCR-13-0709","article-title":"EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss","volume":"20","author":"Sampson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/pcan.2012.49","article-title":"Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer","volume":"16","author":"Sanchez","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2022060700173625800_bib109","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2022060700173625800_bib110","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2022060700173625800_bib111","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/jnci\/dju364","article-title":"Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer","volume":"107","author":"Kobold","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2022060700173625800_bib112","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/cgt.2013.35","article-title":"Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy","volume":"20","author":"Karlsson","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"2022060700173625800_bib113","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/mt.2011.179","article-title":"Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination","volume":"19","author":"Huye","year":"2011","journal-title":"Mol Ther"},{"key":"2022060700173625800_bib114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CJI.0000000000000061","article-title":"BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro","volume":"38","author":"Gargett","year":"2015","journal-title":"J Immunother"},{"key":"2022060700173625800_bib115","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"2022060700173625800_bib116","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/1078-0432.CCR-14-2998","article-title":"K562-Derived whole-cell vaccine enhances antitumor responses of CAR-redirected virus-specific cytotoxic T lymphocytes in vivo","volume":"21","author":"Caruana","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/6\/2\/133\/1824128\/133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/6\/2\/133\/1824128\/133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:18:50Z","timestamp":1654546730000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/6\/2\/133\/5265\/Mesothelin-Targeted-CARs-Driving-T-Cells-to-Solid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":116,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,4]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-15-0583","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546402","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546402.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531278.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22531278","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}